Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
70 hedge funds and large institutions have $137M invested in Merrimack Pharmaceuticals, Inc. in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 9 closing their positions.
3,868% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $47K
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
9% more capital invested
Capital invested by funds: $126M → $137M (+$10.8M)
4% more funds holding
Funds holding: 67 → 70 (+3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$4.96M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$3.72M |
| 3 |
Renaissance Technologies
New York
|
+$1.59M |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$936K |
| 5 |
State Street
Boston,
Massachusetts
|
+$705K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$3.87M |
| 2 |
ICM
Indaba Capital Management
San Francisco,
California
|
-$3M |
| 3 |
Morgan Stanley
New York
|
-$2.52M |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$2.33M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$805K |
MACK Hedge Fund Activity: Q1 2024 in Review
70 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2024, worth a combined $137M — up 8.6% from $126M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MACK positions and 9 closed out — a net gain of 3 holders — while 15 added to existing stakes and 21 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $4.96M. The largest seller was Sio Capital Management, exiting entirely with an estimated $3.87M sold.
- 70 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2024, up from 67 in Q4 2023.
- Funds reported $137M of Merrimack Pharmaceuticals, Inc. stock for Q1 2024, up 8.6% quarter-over-quarter.
- 12 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2024 and 9 closed out, a net change of +3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2024 was ADAR1 Capital Management, an estimated $4.96M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2024 was Sio Capital Management, an estimated $3.87M sold.
Based on aggregated 13F filings for Q1 2024.